Paradigm Biocapital Advisors LP

Q4 2023 13F-HR Holdings

Location
New York, NY
Holdings as of
12/31/2023
Date filed
2/14/2024
Form type
13F-HR
Num holdings
30
Total value ($000)
$2,135,928
Net value change ($000)
+662,275 (44.9%)
New positions
7
Sold out positions
7
Turnover %
19.2%
Sector allocation + QoQ delta (equities-only)
Prev filing: 11/14/2023 Next filing: 5/15/2024 SEC filing

Snapshot: Change Analysis

Compared to Q3 2023
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
NUVL 208,605 277.0%
ACLX 97,096 91.6%
IRON 78,035 130.6%
Ambrx Biopharma, Inc. 61,982 NEW
VRDN 47,946 84.9%
AUTL 47,649 141.9%
XENE 47,027 92.3%
ASND 44,297 NEW
Cerevel Therapeutics Holdings, Inc. 43,519 78.7%
ARVN 38,332 NEW
Top Reduces (Value $000, Stocks/ETFs)
UTHR -69,413 -100.0%
INCY -52,715 -100.0%
Ambrx Biopharma Cayman, Inc. -40,119 -100.0%
SNDX -34,704 -100.0%
LEGN -22,050 -16.2%
VRNA -15,101 -100.0%
ROIV -12,635 -100.0%
BCYC -6,151 -8.4%
COGT -2,200 -100.0%
IMTX -1,341 -5.6%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 2,136 (0.1% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type